| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 840.8 | 856.1 | 620.0 |
| Other income | 25.4 | 35.2 | 5.6 |
| Total income | 866.2 | 891.3 | 625.6 |
| Profit before exceptional items & tax | 206.6 | 200.0 | 76.6 |
| Profit before tax | 206.6 | 200.0 | 76.6 |
| Net profit | 159.4 | 149.0 | 58.2 |
| Operating margin | 23.9% | 22.4% | 12.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +173.90% |
|---|---|
| Net profit, quarter on quarter | +7.00% |
| Revenue, year on year | +35.60% |
| Operating profit, year on year | +155.20% |
| Operating profit, quarter on quarter | +10.00% |
BSE results filing, NSE: MARKSANS. Figures extracted from the filing.
Marksans Pharma Ltd: key numbers
- Share price
- ₹324.40
- Market cap
- ₹14,701 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 28.4×Sector 47.4×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 17.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Annual General Meeting
Marksans Pharma Limited conducted its 34th Annual General Meeting on August 27, 2026. Shareholders considered the adoption of FY2025-26 financial statements and a dividend of Rs. 0.90 per share.
Marksans Pharma Other Announcement
Marksans Pharma Ltd. has received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026.
Marksans Pharma Investor Presentation: Key Takeaways
Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.
- Call
- Guides 20% growth
Marksans Pharma Business Update
Marksans Pharma Ltd submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The filing details operational and sustainability metrics.